We caught up with Prof Joachim Ehrlich (Head of Cardiology and Electrophysiology, St Josefs-Hospital, Wiesbaden, Germany) on the recent studies in the use of pulmonary vein isolation in patients with atrial fibrillation and heart failure and the advantages of cryoballoon ablation compared with radiofrequency ablation. He also gave us an overview of their recent cohort study and its findings.
- What have recent studies taught us about the utility of pulmonary vein isolation in patients with atrial fibrillation and heart failure? (0.18)
- What are the advantages of cryoballoon ablation compared with radiofrequency ablation in the treatment of atrial fibrillation? (2.15)
- Could you give us a brief overview of your cohort study and its findings? (3.12)
- What are the limitations of cryoballoon ablation in this patient population? (4.26)
- What will be the impact of your findings on clinical practice? (5.06)
Speaker’s disclosures: Professor Joachim Ehrlich has nothing to declare in relation to this video interview.
Support: Commissioned, edited and funded by Touch Medical Media.
Filmed during a remote video call with Professor Joachim Ehrlich, September 2020.
Share this Video
Related Videos In Heart Failure
Roxana Mehran, ESC 2021 – the PARADISE-MI Trial
Dr Roxana Mehran (Director of Interventional Cardiovascular Research and Clinical Trials, Icahn School of Medicine, Mount Sinai Hospital, New York City, NY, USA) kindly shared her thoughts on the the PARADISE-MI trial (NCT02924727) from from the virtual ESC Congress 2021. Questions What has been the impact of angiotensin receptor-neprilysin inhibitors (ARNIs) on the treatment of […]
Gilles Montalescot, ESC 2021 – the QUORUM Clinical Study
Prof. Gilles Montalescot (Professor, Pitié-Salpêtrière Hospital, Paris, France) kindly shared his thoughts on the difficulty of treating heart failure after acute myocardial infarction, the use of firibastat and the QUORUM clinical study (NCT03715998) from the virtual ESC Congress 2021. Questions Why does heart failure after acute myocardial infarction remain so challenging to treat? (0.19) Could […]
Diana Bonderman, ESC 2021 – the DYNAMIC Study
Prof. Diana Bonderman (Cardiologist, Medical University of Vienna, Vienna, Austria) kindly shared her thoughts on the current challenges in the treatment of pulmonary hypertension and heart failure with preserved ejection fraction, the mechanism and use of riociguat, and the DYNAMIC study (NCT02744339) from from the virtual ESC Congress 2021. Questions What are the challenges in […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!